<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">15862408</PMID>
<DateCompleted>
<Year>2005</Year>
<Month>05</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0735-1097</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>45</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2005</Year>
<Month>May</Month>
<Day>03</Day>
</PubDate>
</JournalIssue>
<Title>Journal of the American College of Cardiology</Title>
<ISOAbbreviation>J. Am. Coll. Cardiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.</ArticleTitle>
<Pagination>
<MedlinePgn>1392-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We determined the effect of clopidogrel dosing on the incidence of nonresponsiveness (NR) and high post-treatment platelet aggregation (post-PA).</AbstractText>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We have reported NR after a 300-mg loading dose. Limited information is available on the comparative effect of a 600-mg loading dose on the incidence of NR and high post-PA.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Clopidogrel responsiveness and post-PA were measured in patients undergoing stenting (n = 190) randomly treated with either a 300-mg or a 600-mg clopidogrel load. Nonresponsiveness was defined as &lt;10% absolute change in platelet aggregation, and high post-PA was defined as &gt;75th percentile aggregation after 300 mg clopidogrel.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Nonresponsiveness was lower after 600 mg compared to the 300-mg dose (8% vs. 28% and 8% vs. 32% with 5 and 20 microM ADP, respectively, p &lt; 0.001). Among the patients with high post-PA after 300 mg clopidogrel, 62% to 65% had NR, whereas after the 600-mg dose, all of the patients with high post-PA had NR.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A 600-mg clopidogrel loading dose reduces the incidence of NR and high post-PA as compared to a 300-mg dose. Higher dosing strategies and methods to confirm platelet inhibition should be further investigated in order to optimally use clopidogrel in patients undergoing stenting.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gurbel</LastName>
<ForeName>Paul A</ForeName>
<Initials>PA</Initials>
<AffiliationInfo>
<Affiliation>Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA. pgurbel@lifebridgehealth.org</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bliden</LastName>
<ForeName>Kevin P</ForeName>
<Initials>KP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hayes</LastName>
<ForeName>Kevin M</ForeName>
<Initials>KM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yoho</LastName>
<ForeName>Jason A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Herzog</LastName>
<ForeName>William R</ForeName>
<Initials>WR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tantry</LastName>
<ForeName>Udaya S</ForeName>
<Initials>US</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Am Coll Cardiol</MedlineTA>
<NlmUniqueID>8301365</NlmUniqueID>
<ISSNLinking>0735-1097</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>61D2G4IYVH</RegistryNumber>
<NameOfSubstance UI="D000244">Adenosine Diphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>A74586SNO7</RegistryNumber>
<NameOfSubstance UI="D000077144">Clopidogrel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>OM90ZUW7M1</RegistryNumber>
<NameOfSubstance UI="D013988">Ticlopidine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000244">Adenosine Diphosphate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077144">Clopidogrel</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023921">Coronary Stenosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010974">Platelet Aggregation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010975">Platelet Aggregation Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011183">Postoperative Complications</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015607">Stents</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013988">Ticlopidine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2004</Year>
<Month>11</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2004</Year>
<Month>12</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2005</Year>
<Month>01</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2005</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2005</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2005</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">15862408</ArticleId>
<ArticleId IdType="pii">S0735-1097(05)00370-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.jacc.2005.01.030</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>